Abstract We have summarized the latest findings on markers for progression of immunoglobulin A (IgA) nephropathy (IgAN), the most common primary glomerulonephritis with a high prevalence among end-stage renal disease (ESRD) patients. The clinical predictors of renal outcome in IgAN nephropathy, such as proteinuria, hypertension, and decreased estimated glomerular filtration rate (eGFR) at the time of the diagnosis, are well known. The Oxford classification of IgAN identified four types of histological lesions (known as the MEST score) associated with the development of ESRD and/or a 50 % reduction in eGFR. In addition, the role of genetic risk factors associated with IgAN is being elucidated by genome-wide association studies, with multiple risk alleles described. Recently, biomarkers in serum (galactose-deficient IgA1, IgA/IgG autoantibodies against galactose-deficient IgA1, and soluble CD 89-IgA complexes) and urine (soluble transferrin receptor, interleukin-6/epidermal growth factor ratio, fractalkine, laminin G-like 3 peptide, j light chains, and mannan-binding lectin) have been identified. Some of these biomarkers may represent candidates for the development of noninvasive diagnostic tests, that would be useful for detection of subclinical disease activity, monitoring disease progression, assessment of treatment, and at the same time circumventing the complications associated with renal biopsies. These advances, along with future disease-specific therapy, will be helpful in improving the treatment effectiveness, prognosis, and the quality of life in connection with IgAN.
Introduction
Immunoglobulin A (IgA) nephropathy (IgAN) is the most common primary glomerulonephritis, leading to end-stage renal disease (ESRD) in about 30-50 % of patients, necessitating renal replacement therapy, i.e., dialysis or transplantation [1, 2] . Diagnosis of IgAN requires evaluation of renal biopsy specimens and detection of IgA dominant or co-dominant deposits, frequently concomitant with mesangial/endocapillary hypercellularity and fibrosis, as outlined in the Oxford classification [3, 4] . Renal biopsy D. Maixnerova, C. Reily and Q. Bian contributed equally to this review.
is an invasive procedure and has served as a key instrument for diagnosis of IgAN and other glomerulonephritides. However, noninvasive markers of IgAN with diagnostic and prognostic significance would be valuable to complement the currently used clinical and laboratory approaches. In this review, we briefly summarize the current state of the art in this field.
Diagnosis of IgAN depends on the demonstration of mesangial IgA1-dominant or co-dominant immunodeposits (by immunofluorescence or by immunohistochemistry). IgG and/or IgM co-deposits are also detected in about 50 % of cases. Complement C3 is detected in more than 90 % of cases of primary IgAN, whereas C1q is absent. Clinically, microscopic or macroscopic hematuria with or without proteinuria (usually \2 g/24 h) [5] is frequently observed in patients with IgAN at the time of diagnosis. The clinical presentation of hematuria is commonly associated with an upper-respiratory-tract infection. Some patients already have renal impairment and hypertension at initial presentation.
IgAN has been defined as an autoimmune disease that has a multi-hit pathobiological process with genetic and environmental contributing factors (Fig. 1) [2, 6, 7] . Aberrantly glycosylated forms of IgA1 with galactose-deficient O-glycans (galactose-deficient IgA1; Gd-IgA1) play a key role in the pathogenesis of IgAN [8] . Gd-IgA1 molecules are recognized by antiglycan autoantibodies of IgG and/or IgA1 isotype, resulting in the formation of circulating immune complexes [9] . These complexes are not efficiently cleared via the normal hepatic catabolism, resulting in glomerular deposition and mesangial-cell activation, thus inciting the first step of glomerular injury [10] . The glomerular IgA1-containing immune complexes cause local activation of the complement system [11] [12] [13] [14] , proliferation of mesangial cells, production of extracellular matrix and cytokines (e.g., tumor necrosis factor-a, and transforming growth factor-b) [15] , which could alter podocyte gene expression and glomerular permeability. This mesangio-podocyte injury might explain proteinuria and tubulointerstitial changes in IgAN.
Clinical markers
The following clinical predictors of renal outcome in IgAN have been assessed in several clinical studies at the time of diagnosis: proteinuria, hypertension, decreased estimated glomerular filtration rate (eGFR) [2, 16, 17] as well as histological grading [18] . Three risk factors assessed at the time of biopsy, 24-h urinary protein excretion C1.0 g, hypertension ([140/90 mm Hg), and severe histological lesions, were found to be significantly associated with dialysis or death [19] . The 20-year predicted survival and/or dialysis of patients was 64 vs 4 % between those with 3 risk factors and those with none, respectively [19] . Notably, time-averaged proteinuria was the best metric for prognosis of IgAN [20] . Moreover, control of proteinuria over time reduced the risk of future loss of kidney function [21] . These two studies showed that assessment of proteinuria during follow-up is a more powerful independent prognostic predictor than proteinuria at the onset [22] . In addition, age, gender, family medical history, hematuria, and hypoalbuminemia were also found to be associated with progression of IgAN in some studies [23] .
Pathological markers
In 2009, the Oxford classification of IgAN was proposed, and it identified four types of lesions as specific pathologic features associated with the development of ESRD and/or a 50 % reduction in eGFR: mesangial hypercellularity (M0 or M1), endocapillary proliferation (E0 or E1), segmental glomerulosclerosis (S0 or S1), and tubular atrophy/interstitial fibrosis (T0 or T1 or T2) [24] . The combined maximal score of this MEST classification (M1?E1?S1?T2) is 5, and renal lesions with a summing score of 2 or higher were assessed as independent risk factors for progression to ESRD (dialysis or eGFR \15 ml/min/1.73 m 2 ). In addition, each MEST risk factor was proposed as an independent value [24] . The MEST score was independently associated with renal outcome [25] . Pathological risk factors can be associated with other clinical risk factors, such as hypertension, proteinuria and eGFR [24] . The VALIGA study (European Validation Study of the Oxford Classification of IgA Nephropathy) (VALIGA) provided a validation of the Oxford classification in a large European cohort of IgAN patients [26] .
IgG co-deposits are very common and present in around 45-60 % of IgAN biopsies. Earlier studies showed that IgAN-circulating immune complexes containing aberrantly glycosylated IgA1 bind to mesangial cells more efficiently than uncomplexed IgA. Localization of IgA with IgG in the mesangium and glomerular capillary walls correlated with higher mesangial and endocapillary cellularity scores [27] . A small-cohort study verified that mesangial IgG deposition in patients with IgAN was associated with more severe clinical features, including more capillary-wall IgA deposits and persistent urinary abnormalities [28] . Multivariate analysis indicated that a high initial chronicity index, erythrocyturia, and mesangial IgG co-deposits were independent determinants of disease progression. These data indicate that IgG co-deposits may be involved in the development of mesangial proliferative changes. Staining for complement factors, such as C3, C4d, C5b-9, and Fig. 1 Summary of biomarkers related to the progression of IgAN (based on a multi-hit pathogenesis scheme of IgAN [35] ). The scheme shows the hypothesis of IgAN, wherein multiple conditions (hits) are required for disease development. ''Hit 1'' is elevated levels of circulating Gd-IgA1, which is a necessary but not sufficient condition for disease development. The second hit, ''Hit 2'' is production of autoantibodies (IgG/IgA isotype) that recognize GdIgA1. ''Hit 3'' describes formation of circulating immune complexes from Gd-IgA1 and the corresponding autoantibodies. ''Hit 4'' is driven by the deposition of these Gd-IgA1-containing pathogenic immune complexes in the mesangium and mesangial-cell activation inciting glomerular injury. Corresponding to each part of the multi-hit hypothesis is a list of IgAN-associated markers J Nephrol (2016) 29:535-541 537 mannan-binding lectin, may provide additional insight into the disease mechanism [28, 64, 65] .
Biomarkers in the serum and urine
Recently identified serum and urine biomarkers ( Fig. 1 [29, 30, 45, 46] . Moldoveanu et al. [32] showed increased serum levels of Gd-IgA1 in IgAN patients compared to healthy controls of Caucasian ancestry, and other studies showed similar results for patients of Asian [43] and African-American ancestry [33] . In children, including Caucasians and African-Americans, serum levels of Gd-IgA1 were elevated, but not associated with proteinuria.
A strong association between the serum level of GdIgA1 and progression of IgAN has also been shown [34] . Recent data showed the potential for lectin-independent Gd-IgA1-specific assessment using a monoclonal antibody, KM55, which could facilitate the use of clinical measurement of this biomarker [44] . However, this assay has yet to be validated in other cohorts and precise specificities of the antibody are to be elucidated.
High levels of Gd-IgA1-specific IgG and IgA autoantibodies predict disease progression of IgAN [45] . Levels of serum IgG autoantibodies correlate with proteinuria and levels of IgG-IgA1 immune complexes excreted in the urine [46] . It was suggested that biomarkers, such as serum levels of Gd-IgA1 and the corresponding autoantibodies may be useful for monitoring/predicting the progression of disease and/or evaluating responses to therapy [47, 48] .
The role of micro RNA (miRNA) in patients with IgAN has been investigated [49] . For example, abnormal miR-148b expression is associated with elevated production of Gd-IgA1 in peripheral blood mononuclear cells of IgAN patients [50] .
Another study showed down-regulated urinary expression of miR-3613-3p in patients with IgAN [51] . Moreover, urinary levels of both miR-3613-3p and miR-4668-5p correlated with disease severity [51] and miR-29b-3p is down regulated in renal tissue of IgAN patients [52] . miR-29b-3p down-regulation caused CDK6 overexpression, that promotes NF-jB signal by phosphorylating p65 which might enhance inflammation in IgAN [52] . Moreover, miR-223 expression in glomerular endothelial cells was associated with glomerular endothelial cell activation and was proposed as a noninvasive marker for evaluating the severity of IgAN [53] . It is not clear at this time, whether assessment of miRNA expression profile(s) may be used clinically and how predictive it may be of disease progression.
In addition, it was hypothesized that elevated soluble IgA receptor CD89 (sCD89) may be protective against progressive renal injury in IgAN [38] . However, this a1-and b2-microglobulin Correlates with proteinuria [42] Kidney injury molecule-1 (KIM-1) Correlates with proteinuria, combined with serum creatinine correlates with poor renal outcome [41] Interleukin-6/epidermal growth factor (IL-6/EGF) Marker of IgAN progression, correlates with renal outcome [56] Epidermal growth factor/monocyte chemotactic protein-1 (EGF/MCP-1)
Correlates with histologic severity and renal prognosis [57] Fractalkine Correlates with pathogenesis of immune complex-mediated glomerulonephritis [58] Laminin G-like 3 peptide (perlecan) Decreased levels inversely correlate with histological features [59] Free kappa light chains Decreased levels inversely correlate with histological features [59] Uromodulin Increased levels predict IgAN [60] a-1 antitrypsin Increased levels in the urine associate with nephrotic syndrome [61] Podocalyxin Associates with histologic kidney injury [62] Mannose-binding lectin Correlates with renal function and proteinuria [64] C4a desArg peptide Associates with severe histological changes in IgAN [65] IgAN immoglobulin A nephropathy, HSP Henoch-Schönlein purpura clinical observation is in contrast with a previously postulated pathogenic role of sCD89-IgA1 complexes [37] . Potentially, after clarification of the contrasting data, sCD89 may become a prognostic marker of the risk of ESRD or recurrent disease after transplantation, as recently published [54] . For potential urinary markers, median levels of urinary soluble transferrin receptor (sTfR) were reported to be elevated in patients with active IgAN and a related disease, Henoch-Schöenlein purpura nephritis [40] . Urinary KIM-1 correlated with proteinuria, but not with b2-microglobulin [41, 42] . Urinary excretion of KIM-1 above median was associated with poor renal outcome in patients with serum creatinine [135 lmol/L. This study showed that urinary excretion of KIM-1 was a better predictor of renal outcome than proteinuria [41] . Even for patients with clinically mild IgAN (normotension, normal renal function and proteinuria \1.0 g/24 h), high urinary KIM-1 can be predictive of severe morphological changes found in kidney biopsies [55] .
The urinary IL-6/EGF ratio was found to be a marker of the progression of IgAN [56] . Urinary IL-6/EGF ratio was related to the severity of the disease and also predicted renal outcome. The ratio of EGF/MCP-1 in the urine was related to the severity of histologic lesions and significantly predicted renal prognosis in 132 patients with IgAN [57] . Urinary concentrations of another proinflammatory chemokine, fractalkine, and MCP-1 showed a significant inverse correlation with eGFR, and may be useful for predicting the activity of IgAN [58] .
Decreased urinary levels of laminin G-like 3 peptide (perlecan) and free j light chains were observed in patients with IgAN, and the levels of both inversely correlated with severity of clinical and histological features of IgAN patients [59] .
Another study identified a fragment of uromodulin in urine samples from patients with IgAN compared to healthy controls and patients with other glomerulonephritides [60] . Other urinary markers, such as a-1 antitrypsin and podocalyxin, have been detected in patients with severe IgAN [61, 62] . It was assumed that urinary podocalyxin was associated with severity of active glomerular injury in patients with glomerular diseases including IgAN [62] .
A number of studies focused on the analyses of urinary peptidome and its changes in chronic renal diseases, including IgAN [63] . Future studies will determine whether there are any urinary peptides of prognostic significance.
Complement factors and their fragments may serve as biomarkers of IgAN in serum, urine, or renal tissue [11, 12] . The level of urinary mannan-binding lectin was significantly associated with renal function and proteinuria in a Chinese study of 162 patients with IgAN [64] . A low level of urinary mannan-binding lectin at the time of renal biopsy was associated with better clinical outcome and histological renal findings [64] . Another study found an association of urinary peptide fragment, and complement component C4a desArg, with histological severe forms of IgAN [65] .
Genetic markers
The role of genetic factors for susceptibility to IgAN has been demonstrated [66] . Genome-wide association studies in IgAN patients identified multiple risk loci associated with IgAN [67, 68] . Future assays, derived from a singlenucleotide polymorphism (SNP)-based risk score and the number of risk-associated alleles, may offer a valuable tool to predict progression of disease in addition to explaining the risk of disease and age of onset (Fig. 1 ).
Conclusions
There are many possible candidate biomarkers of IgAN that need to be validated in larger cohorts of patients and controls before they can be introduced into clinical practice. The development of noninvasive diagnostic tests would also be useful for evaluation of disease activity, monitoring disease progression and assessment of treatment effectiveness. Some IgAN biomarkers are linked to basic pathways of disease pathogenesis, as summarized in Fig. 1 and Table 1 . For example, IgAN patients with high serum levels of Gd-IgA1 and/or IgG and IgA autoantibodies have worse prognosis, and will need close follow-up and more aggressive treatment to control clinical risk factors (proteinuria and hypertension). Moreover, some markers, such as anti-Gd-IgA1 autoantibodies, might represent a disease-specific marker and potential therapeutic target [45] . The patients with substantial disease activity (based on the clinical and histological findings) could benefit with from an early initiation of immunosuppressive treatment to reduce the incidence of ESRD. These clinical improvements will ultimately reduce the costs otherwise needed to cover renal replacement therapy (hemodialysis, peritoneal dialysis, and kidney transplantation).
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